Complete Regression of Lung Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer Using 177Lu-PSMA Radioligand Therapy.
Clin Nucl Med
; 45(1): e48-e50, 2020 Jan.
Article
de En
| MEDLINE
| ID: mdl-31162261
ABSTRACT
Patients with metastatic castration-resistant prostate cancer (mCRPC) and visceral (liver or lung) metastases have a poor prognosis and worse outcomes than those with bone disease with or without lymph nodes involvement. The high prostate-specific membrane antigen expression in prostate cancer metastases makes it a promising approach for targeted radionuclide therapy of prostate cancer. Lutetium-177 (Lu)-labeled prostate-specific membrane antigen radioligand therapy (Lu-PRLT) has demonstrated encouraging efficacy in mCRPC. We report here an mCRPC patient with lung, lymph nodes, and extensive bone metastases, who underwent Lu-PRLT and had excellent response to the treatment and complete regression of lung metastases after Lu-PRLT.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Dipeptides
/
Tumeurs prostatiques résistantes à la castration
/
Composés hétéromonocycliques
/
Tumeurs du poumon
Type d'étude:
Prognostic_studies
Limites:
Humans
/
Male
/
Middle aged
Langue:
En
Journal:
Clin Nucl Med
Année:
2020
Type de document:
Article
Pays d'affiliation:
Allemagne